Literature DB >> 27732988

Obstacles to and Solutions for a Successful Lung Cancer Screening Program.

Peter J Mazzone1.   

Abstract

Lung cancer screening with a low radiation dose chest CT scan has been shown to reduce the number of people, in a well-defined very high-risk cohort, who die from lung cancer. Many potential screening-related harms have been identified, including anxiety and morbidity related to the evaluation of screen-detected findings. A favorable balance of the benefit and harms of lung cancer screening requires careful implementation of a screening program, with a focus on several obstacles to the success of the program. In this review, evidence to support the benefit and harms of lung cancer screening is provided, followed by a discussion of 11 obstacles to the development of a high-quality program. For each obstacle, an approach is suggested, based on evidence and mandates as well as practicality and lessons learned. The approach to each of these obstacles highlights the multi-disciplinary nature of lung cancer screening, and the value of considering lung cancer screening a program rather than a test. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27732988     DOI: 10.1055/s-0036-1592114

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  2 in total

Review 1.  Chronic obstructive pulmonary disease (COPD) and lung cancer screening.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Transl Lung Cancer Res       Date:  2018-06

2.  Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.

Authors:  Peter J Mazzone; Catherine Rufatto Sears; Doug A Arenberg; Mina Gaga; Michael K Gould; Pierre P Massion; Vish S Nair; Charles A Powell; Gerard A Silvestri; Anil Vachani; Renda Soylemez Wiener
Journal:  Am J Respir Crit Care Med       Date:  2017-10-01       Impact factor: 21.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.